Core Insights - GeneDx Holdings experienced a significant stock increase of over 8% following a strong second-quarter earnings report, contrasting with a 0.3% decline in the S&P 500 index [1] Financial Performance - The company reported nearly $103 million in revenue for the second quarter, marking a 49% year-over-year growth, driven by a 69% increase in exome and genome testing services, totaling 23,102 tests [2] - GeneDx achieved a non-GAAP net income of just under $15 million, a turnaround from a loss of over $2 million in the same quarter of the previous year, equating to earnings of $0.50 per share [4] - Both revenue and adjusted net income figures exceeded analyst expectations, with consensus estimates at approximately $85 million in revenue and an adjusted net income of $0.12 per share [5] Future Guidance - The company raised its revenue guidance for 2025 to a range of $400 million to $415 million, up from a previous estimate of $360 million to $375 million, largely due to anticipated growth in exome and genome revenue, now projected to increase by 48% to 52% over 2024 figures, compared to an earlier estimate of 30% [6] - GeneDx maintained its guidance for adjusted net income growth, indicating it will remain a positive figure for each quarter and for the year overall, though specifics were not provided [7]